Literature DB >> 11085537

Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.

L C Amler1, D B Agus, C LeDuc, M L Sapinoso, W D Fox, S Kern, D Lee, V Wang, M Leysens, B Higgins, J Martin, W Gerald, N Dracopoli, C Cordon-Cardo, H I Scher, G M Hampton.   

Abstract

Treatment of metastatic prostate cancer with androgen-ablation often elicits dramatic tumor regressions, but the response is rarely complete, making clinical recurrence inevitable with time. To gain insight into therapy-related progression, changes in gene expression that occurred following androgen-deprivation of an androgen-dependent prostate tumor xenograft, CWR22, and the emergence of an androgen-independent tumor, CWR22-R, were monitored using microarray analysis. Androgen-deprivation resulted in growth arrest of CWR22 cells, as evidenced by decreased expression of genes encoding cell cycle components and basal cell metabolism, respiration and transcription, and the induced expression of putative negative regulatory genes that may act to sustain cells in a nonproliferative state. Evolution of androgen-independent growth and proliferation, represented by CWR22-R, was associated with a reentry into active cell cycle and the up-regulation of several genes that were expressed at low levels or absent in the androgen-dependent tumor. Androgen repletion to mice bearing androgen-independent CWR22-R tumors induced, augmented, or repressed the expression of a number of genes. Expression of two of these genes, the calcium-binding protein S100P and the FK-506-binding protein FKBP51, was decreased following androgen-deprivation, subsequently reexpressed in CWR22-R at levels comparable with CWR22, and elevated further upon treatment with androgens. The dysregulated behavior of these genes is analogous to other androgen-dependent genes, e.g., prostate-specific antigen and human kallikrein 2, which are commonly reexpressed in androgen-independent disease in the absence of androgens. Other androgen-responsive genes whose expression decreased during androgen-deprivation and whose expression remained decreased in CWR22 were also identified in CWR22-R. These results imply that evolution to androgen-independence is due, in part, to reactivation of the androgen-response pathway in the absence of androgens, but that this reactivation is probably incomplete.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085537

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Expression profiling of human tumors: the end of surgical pathology?

Authors:  M Ladanyi; W C Chan; T J Triche; W L Gerald
Journal:  J Mol Diagn       Date:  2001-08       Impact factor: 5.568

2.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

Authors:  Jeff Holzbeierlein; Priti Lal; Eva LaTulippe; Alex Smith; Jaya Satagopan; Liying Zhang; Charles Ryan; Steve Smith; Howard Scher; Peter Scardino; Victor Reuter; William L Gerald
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

3.  The program of androgen-responsive genes in neoplastic prostate epithelium.

Authors:  Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

Review 4.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

5.  Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P.

Authors:  Max Koltzscher; Claudia Neumann; Simone König; Volker Gerke
Journal:  Mol Biol Cell       Date:  2003-06       Impact factor: 4.138

6.  Heterodimeric interaction and interfaces of S100A1 and S100P.

Authors:  Guozheng Wang; Shu Zhang; David G Fernig; David Spiller; Marisa Martin-Fernandez; Hongmei Zhang; Yi Ding; Zihe Rao; Philip S Rudland; Roger Barraclough
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

7.  Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids.

Authors:  Tina R Hubler; Jonathan G Scammell
Journal:  Cell Stress Chaperones       Date:  2004       Impact factor: 3.667

Review 8.  S100P: a novel therapeutic target for cancer.

Authors:  Thiruvengadam Arumugam; Craig D Logsdon
Journal:  Amino Acids       Date:  2010-05-28       Impact factor: 3.520

9.  Targeted ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor transcriptional activity.

Authors:  Irene M Wolf; Sumudra Periyasamy; Terry Hinds; Weidong Yong; Weinian Shou; Edwin R Sanchez
Journal:  J Steroid Biochem Mol Biol       Date:  2008-11-27       Impact factor: 4.292

10.  Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes.

Authors:  Cindy R Sinars; Joyce Cheung-Flynn; Ronald A Rimerman; Jonathan G Scammell; David F Smith; Jon Clardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.